Sotalol is a unique agent combining beta-blocking and class III anti-arrhythmic effects, making it useful for supraventricular and ventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
Sotalol's dual mechanism may inform arrhythmia management; leaves open comparative efficacy versus newer agents in contemporary cohorts.
Initially synthesized in 1960, sotalol is a novel beta-adrenoreceptor blocking agent that also possesses class III anti-arrhythmic properties. The drug's ability to lengthen repolarization and prolong effective refractory periods in all cardiac tissues in addition to its beta-blocking effects make sotalol an attractive agent for use in a variety of supraventricular and ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
David Leibowitz (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: